NSCLC STAGE III
Clinical trials for NSCLC STAGE III explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE III trials appear
Sign up with your email to follow new studies for NSCLC STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy before lung cancer surgery shows promise in early trial
Disease control Recruiting nowThis study is for people with stage II or III non-small cell lung cancer that can be removed with surgery. Before surgery, participants will receive a combination of two immunotherapy drugs (sintilimab and IBI310) plus chemotherapy. The goal is to see if this treatment shrinks th…
Matched conditions: NSCLC STAGE III
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Hormone-Immuno combo takes on advanced lung cancer
Disease control Recruiting nowThis study tests whether combining a hormone therapy (leuprorelin) with an immunotherapy drug (sintilimab) can help control advanced lung cancer in men aged 60 and older. The goal is to see if the hormone treatment boosts the immune system to make the immunotherapy work better. A…
Matched conditions: NSCLC STAGE III
Phase: NA • Sponsor: Jinzhou Medical University • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
Blood test guides stronger lung cancer therapy in new trial
Disease control Recruiting nowThis study is for people with stage III non-small cell lung cancer who have already had chemotherapy and radiation. Researchers want to see if adding another drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA in the blo…
Matched conditions: NSCLC STAGE III
Phase: PHASE3 • Sponsor: Maximilian Diehn • Aim: Disease control
Last updated May 26, 2026 04:10 UTC
-
New hope for frail lung cancer patients: targeted drug shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors and be well-tolerated in this group, who are often left out of other trials. Part…
Matched conditions: NSCLC STAGE III
Phase: PHASE2 • Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Tailored workouts for lung cancer: a new pilot study
Symptom relief Recruiting nowThis study tests whether a custom exercise program, delivered via telehealth, is practical for people with stage II or III lung cancer who are getting chemotherapy, immunotherapy, or surgery. Researchers will track how many patients join and stick with the program, and monitor sa…
Matched conditions: NSCLC STAGE III
Phase: NA • Sponsor: University of Utah • Aim: Symptom relief
Last updated May 20, 2026 11:56 UTC